Terodiline
Based on 1 Customer Validation
Terodiline, an antispasmodic agent, blocks hERG current with the IC50 of 375 nM. Terodiline has both anticholinergic and calcium antagonist properties, and effectively reduces abnormal bladder contractions caused by detrusor instability. Terodiline can be used for the research of urinary incontinence.
For research use only. We do not sell to patients.
- Purity : 99.41%
- CAS No.: 15793-40-5
- Formula: C20H27N
- Molecular Weight:281.44
-
Storage:Pure form -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All Calcium Channel Isoforms
More
Biological Activity
Description
IC50 & Target
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | IC50 |
4.8 μM
Compound: terodiline
|
Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits
Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits
|
[PMID: 23812503] |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Fmale or male Hartley guinea pigs (200-600 g)[1]
-
Dosage:80 mg/kg
-
Administration:Administered S.C.
-
Result:Yielded an ID50 of 24±6 mg/kg. Higher doses were Iethal.
Chemical Information
-
CAS No. 15793-40-5
-
Appearance Liquid
-
Molecular Weight 281.44
-
Formula C20H27N
-
Color Colorless to light yellow
-
SMILES
CC(NC(C)(C)C)CC(C1=CC=CC=C1)C2=CC=CC=C2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Pure form -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Purity & Documentation
-
Data Sheet (272 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Ruth L Martin, et al. In vitro preclinical cardiac assessment of tolterodine and terodiline: multiple factors predict the clinical experience. J Cardiovasc Pharmacol. 2006 Nov;48(5):199-206. [Content Brief]
[2]. H D Langtry, et al. Terodiline. A review of its pharmacological properties, and therapeutic use in the treatment of urinary incontinence. Drugs. 1990 Nov;40(5):748-61. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Terodiline Related Classifications
HY-16489 Related Classifications
Powered by Bioz